Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials

Abstract Background While indirect comparison of infliximab (IFX) and vedolizumab (VDZ) in adults with Crohn’s disease (CD) or ulcerative colitis (UC) shows that IFX has better effectiveness during induction, and comparable efficacy during maintenance treatment, comparative data specific to subcutan...

Descripció completa

Dades bibliogràfiques

Autors principals:	Laurent Peyrin‐Biroulet, Perttu Arkkila, Alessandro Armuzzi, Silvio Danese, Marc Ferrante, Jordi Guardiola, Jørgen Jahnsen, Edouard Louis, Milan Lukáš, Walter Reinisch, Xavier Roblin, Philip J Smith, Taek Kwon, Jeeyoung Kim, Sangwook Yoon, Dong-Hyeon Kim, Raja Atreya
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2024-03-01
Col·lecció:	BMC Gastroenterology
Matèries:	Biobetter Bioinnovative Inflammatory bowel disease Subcutaneous infliximab Tumour necrosis factor-α inhibitors Vedolizumab
Accés en línia:	https://doi.org/10.1186/s12876-024-03163-5
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!